Amit Akirov1,2, Tzipora Shochat3, Amir Shechvitz4, Ilan Shimon4,5, Talia Diker-Cohen4,5,6, Eyal Robenshtok4,5. 1. Institute of Endocrinology, Rabin Medical Center-Beilinson Hospital, Petach-Tikva, Israel. amit.akirov@gmail.com. 2. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. amit.akirov@gmail.com. 3. Statistical Consulting Unit, Rabin Medical Center-Beilinson Hospital, Petach-Tikva, Israel. 4. Institute of Endocrinology, Rabin Medical Center-Beilinson Hospital, Petach-Tikva, Israel. 5. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 6. Internal Medicine A, Rabin Medical Center-Beilinson Hospital, Petach-Tikva, Israel.
Abstract
CONTEXT: Limited data is available regarding the association between pre-admission thyroid function and prognosis of hospitalized patients treated for hypothyroidism. OBJECTIVE: Evaluate an association between thyroid stimulating hormone (TSH) levels and mortality in hospitalized levothyroxine-treated patients. DESIGN AND SETTING: Observational data of patients admitted to medical wards between 2011 and 2013. TSH levels obtained up to 180 days prior to admission were stratified as follows: low (≤0.5 mIU/L), normal (0.5-5 mIU/L), high (>5 mIU/L). PATIENTS: Patients aged 60-80 years with available thyroid function tests were matched with controls without hypothyroidism. MAIN OUTCOME: All-cause mortality up to 66-months following discharge. RESULTS: One thousand and fifty seven patients (73% females, mean (SD) age 71 ± 6 years) were matched with controls without hypothyroidism. Mean hospital stay and in-hospital mortality were not different between groups. Mortality risk at the end-of-follow-up was 41% (438/1057) and 37% (392/1057) for patients with and without hypothyroidism (p < 0.05). TSH levels were classified as follows: low, 84 patients (8%); normal, 667 patients (63%); high, 306 patients (29%). Length of hospitalization and in-hospital mortality were not different between TSH categories. Mortality risk at the end-of-follow-up was 30, 39, and 50% with low, normal and elevated TSH, respectively. Adjusted hazard ratio (95% CI) of mortality at the end-of-follow-up was of 2.2 (1.2-3.8) for high vs. low TSH levels, and 1.4 (1.1-1.9) for high vs. normal TSH levels. CONCLUSION: In treated hypothyroid adult patients, increased TSH up to 6 months prior to admission is associated with increased mortality. Treatment should aim at achieving euthyroidism to improve survival.
CONTEXT: Limited data is available regarding the association between pre-admission thyroid function and prognosis of hospitalized patients treated for hypothyroidism. OBJECTIVE: Evaluate an association between thyroid stimulating hormone (TSH) levels and mortality in hospitalized levothyroxine-treated patients. DESIGN AND SETTING: Observational data of patients admitted to medical wards between 2011 and 2013. TSH levels obtained up to 180 days prior to admission were stratified as follows: low (≤0.5 mIU/L), normal (0.5-5 mIU/L), high (>5 mIU/L). PATIENTS: Patients aged 60-80 years with available thyroid function tests were matched with controls without hypothyroidism. MAIN OUTCOME: All-cause mortality up to 66-months following discharge. RESULTS: One thousand and fifty seven patients (73% females, mean (SD) age 71 ± 6 years) were matched with controls without hypothyroidism. Mean hospital stay and in-hospital mortality were not different between groups. Mortality risk at the end-of-follow-up was 41% (438/1057) and 37% (392/1057) for patients with and without hypothyroidism (p < 0.05). TSH levels were classified as follows: low, 84 patients (8%); normal, 667 patients (63%); high, 306 patients (29%). Length of hospitalization and in-hospital mortality were not different between TSH categories. Mortality risk at the end-of-follow-up was 30, 39, and 50% with low, normal and elevated TSH, respectively. Adjusted hazard ratio (95% CI) of mortality at the end-of-follow-up was of 2.2 (1.2-3.8) for high vs. low TSH levels, and 1.4 (1.1-1.9) for high vs. normal TSH levels. CONCLUSION: In treated hypothyroid adult patients, increased TSH up to 6 months prior to admission is associated with increased mortality. Treatment should aim at achieving euthyroidism to improve survival.
Authors: Pedro Iglesias; Elena Ridruejo; Angélica Muñoz; Florentino Prado; María Cruz Macías; María Teresa Guerrero; Pilar Tajada; Carmen García-Arévalo; Juan José Díez Journal: J Clin Endocrinol Metab Date: 2013-10-30 Impact factor: 5.958
Authors: Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka Journal: Thyroid Date: 2014-12 Impact factor: 6.568
Authors: Anne R Cappola; Linda P Fried; Alice M Arnold; Mark D Danese; Lewis H Kuller; Gregory L Burke; Russell P Tracy; Paul W Ladenson Journal: JAMA Date: 2006-03-01 Impact factor: 56.272
Authors: David Nanchen; Jacobijn Gussekloo; Rudi G J Westendorp; David J Stott; J Wouter Jukema; Stella Trompet; Ian Ford; Paul Welsh; Naveed Sattar; Peter W Macfarlane; Simon P Mooijaart; Nicolas Rodondi; Anton J M de Craen Journal: J Clin Endocrinol Metab Date: 2012-01-11 Impact factor: 5.958
Authors: Nicolas Ochs; Reto Auer; Douglas C Bauer; David Nanchen; Jacobijn Gussekloo; Jacques Cornuz; Nicolas Rodondi Journal: Ann Intern Med Date: 2008-05-19 Impact factor: 25.391